BACKGROUND: Until now prognostic evaluation for patients with oral squamous cell carcinoma (OSCC) remains difficult. Thus, the aim of the present study was to ascertain the value of Ki-67 expression in predicting locoregional recurrence in OSCC. METHODS: In a large, homogeneous study population consisting of 166 patients with OSCC exclusively treated with primary surgery, expression of Ki-67 was investigated by immunohistochemistry. RESULTS: We report that high proliferation significantly correlated to a higher risk of locoregional recurrence in stage I OSCC patients (p = .029). Carcinomas with a Ki-67 labeling index above the median showed a mean time to recurrence of 42 months, whereas mean time to recurrence was 55 months for those tumors below the median (p = .017). CONCLUSIONS: This study provides the evidence of a predictive value of Ki-67 expression in stage I OSCC. Therefore, Ki-67 expression level could be used to identify a subgroup of surgically treated patients with stage I OSCC who might benefit from treatment intensification.
BACKGROUND: Until now prognostic evaluation for patients with oral squamous cell carcinoma (OSCC) remains difficult. Thus, the aim of the present study was to ascertain the value of Ki-67 expression in predicting locoregional recurrence in OSCC. METHODS: In a large, homogeneous study population consisting of 166 patients with OSCC exclusively treated with primary surgery, expression of Ki-67 was investigated by immunohistochemistry. RESULTS: We report that high proliferation significantly correlated to a higher risk of locoregional recurrence in stage I OSCC patients (p = .029). Carcinomas with a Ki-67 labeling index above the median showed a mean time to recurrence of 42 months, whereas mean time to recurrence was 55 months for those tumors below the median (p = .017). CONCLUSIONS: This study provides the evidence of a predictive value of Ki-67 expression in stage I OSCC. Therefore, Ki-67 expression level could be used to identify a subgroup of surgically treated patients with stage I OSCC who might benefit from treatment intensification.
Authors: Melody T Tan; Jean G Wu; Juan Luis Callejas-Valera; Richard A Schwarz; Ann M Gillenwater; Rebecca R Richards-Kortum; Nadarajah Vigneswaran Journal: Int J Exp Pathol Date: 2020-05-21 Impact factor: 1.925
Authors: Alexander W Eckert; Claudia Wickenhauser; Paul C Salins; Matthias Kappler; Juergen Bukur; Barbara Seliger Journal: J Transl Med Date: 2016-04-05 Impact factor: 5.531
Authors: Marta Woźniak; Marek Nahajowski; Sylwia Hnitecka; Monika Rutkowska; Grzegorz Marek; Anil Agrawal; Sebastian Makuch; Siddarth Agrawal; Piotr Ziółkowski Journal: Transl Cancer Res Date: 2020-02 Impact factor: 1.241